Spyre Therapeutics to Report SPY001 Topline UC Results; Six Phase II Readouts Expected in 2026
Spyre will present SPY001 topline results in ulcerative colitis on April 13, 2026. Six Phase 2 readouts are expected in 2026; Q1 net loss was $69 million.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) will report SPY001 Part A induction topline results from the SKYLINE trial in patients with moderate-to-severely active ulcerative colitis on Monday, April 13, 2026, followed by a conference call and webcast at 8:00am ET. SPY001 achieved high remission and endoscopic improvement rates, surpassing prior ulcerative colitis trial benchmarks.
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Its pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
The company expects six Phase 2 proof-of-concept readouts in 2026, with cash runway into 2028. It is also advancing co-formulated antibody combinations in autoimmune diseases, with nine key readouts ahead. In Q1 2026, Spyre reported a net loss of $69 million, while maintaining a strong cash position. The company is seeking up to $154 million via an at-the-market stock sale to fund its antibody pipeline and growth.
At the 2026 annual meeting held virtually on May 27, 2026, shareholders voted on four proposals: election of Class I directors, advisory approval of executive compensation, ratification of KPMG as auditor, and approval of the amended 2016 employee stock purchase plan. The board recommended voting in favor of all proposals.